Antiangiogenic therapy of age-related degeneration of the macula
DOI:
https://doi.org/10.31288/oftalmolzh2015393100Keywords:
age-related macular degeneration, vascular endothelial growth factor inhibitor, ranibizumab, aflibercept, bevacizumabAbstract
Antiangiogenic therapy of age-related degeneration of the macula
References
CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration/ Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ// N Engl J Med. - 2011. - 364(20). - С.1897-1908. https://doi.org/10.1056/NEJMoa1102673
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results/ Martin DF, Maguire MG, Fine SL, et al. // Ophthalmology. - 2012. - 119(7). - С.1388-1398.https://doi.org/10.1016/j.ophtha.2012.03.053
IVAN Study Investigators. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial/ Chakravarthy U, Harding SP, Rogers CA, et al. // Ophthalmology. - 2012. - 119(7). - С.1399-1411.https://doi.org/10.1016/j.ophtha.2012.04.015
Kodjikian L. Overview of the GEFAL Study. Presented at: The Association for Research in Vision and Ophthalmology Annual Meeting/ Seattle, WA. - May 5-9. - 2013.
Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration/ VIEW 1 and VIEW 2 Study Groups// Ophthalmology. - 2012. - 119(12). - С.2537-2548.https://doi.org/10.1016/j.ophtha.2012.09.006
Stewart MW. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)/ Rosenfeld PJ, Penha FM, et al. // Retina. - 2012. - 32. - С.434-457.https://doi.org/10.1097/IAE.0b013e31822c290f
Hisatomi T. OCT predicts VEGF levels in human eyes/ Invest Ophthalmol VisSci. - 2013. - 54. - С.53-75.https://doi.org/10.1167/iovs.13-12846
Schmidt-Erfurth U. Intravitreal afli bercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies/ Kaiser PK, Korobelnik JF, et al. // Ophthalmology. - 2013. - 120(9). - Doi: 10.1016. - j.ophtha. - 2013.08.011.
Rofagha S. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP)/ Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group// Ophthalmology. - 2013 May 3. - [Epub ahead of print].https://doi.org/10.1016/j.ophtha.2013.03.046
Kahook MY. High-molecular-weight aggregates in repackaged bevacizumab/ Liu L, Ruzycki P, et al. // Retina. - 2010. - 30(6). - С. 887-892.https://doi.org/10.1097/IAE.0b013e3181d50cea
Avery R. Visual acuity response as a function of the affinity and vitreous half-life of intravitreally administered anti-VEGF agents/ Presented at: American Society of Retina Specialists 2012// Las Vegas, NV.
HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration/ Busbee BG, Ho AC, Brown DM, et al; // Ophthalmology. - 2013. - 120(5). - С.1046-1056.https://doi.org/10.1016/j.ophtha.2012.10.014
European Medicines Agency. Assessment report [aflibercept]/ Procedure No. EMEA/H/C/002392/ http://www.ema.europa.eu/docs/en_GB/ document_library// EPAR-Public_assessment_report/human/002392/ WC500135744.pdf. - Аccessed June 27, 2013.
Boyer DS. Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration/ Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A// Ophthalmology. - 2009. - 116(9). - С.1731-1739.https://doi.org/10.1016/j.ophtha.2009.05.024
MONT BLANC Study Group. Verteporfin plus ranibizumab for Choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results/ Larsen M, Schmidt-Erfurth U, Lanzetta P, et al; //Ophthalmology. - 2012. - 119(5). - С.992-1000.https://doi.org/10.1016/j.ophtha.2012.02.002
Koh A. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy/ Lee WK, Chen LJ, et al.// Retina. - 2012. - 32(8). - С.1453-1464.https://doi.org/10.1097/IAE.0b013e31824f91e8
Tozer K. Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents/ Roller AB, Chong LP, et al.// Ophthalmology. - 2013. - 120(10). - С. 2029-2034.https://doi.org/10.1016/j.ophtha.2013.03.016
MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration/ Rosenfeld PJ, Brown DM, Heier JS, et al; // N Engl J Med. - 2006. - 355(14). - С.1419-1431.https://doi.org/10.1056/NEJMoa054481
ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration/ Brown DM, Kaiser PK, Michels M, et al; // N Engl J Med. - 2006. - 355(14). - С.1432-1444.https://doi.org/10.1056/NEJMoa062655
Lad EM. Treatment patterns in neovascular age-related macular degeneration between 2005-2010/ Hammill BG, Qualls LG, Wang F, Cousins SW, Curtis LH// Paper presented at: The Association for Research in Vision and Ophthalmology Annual Meeting. - Мay 5-9, 2013. - Seattle, WA. - Abstract 3819-B0129.
Holekamp NM. Real-world utilization of intravitreal antivascular endothelial growth factor agents in retinal diseases: A Claims Analysis from 2006 to 2011/ Yeh W-S, Chia YJ, Kiss S, Almony A, Kowalski J.// Paper presented at: American Society of Retina Specialists Annual Meeting. - Аugust 25-29. - 2012. - Las Vegas, NV.
Shienbaum G. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact/ Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD// Am J Ophthalmol. - 2012. - 153(3). - С.468-473.e1.https://doi.org/10.1016/j.ajo.2011.08.011
Gupta OP. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact/ Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD// Ophthalmology. - 2010. - 117(11). - С.2134-2140.https://doi.org/10.1016/j.ophtha.2010.02.032
Oubraham H. Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration/ Cohen SY, Samimi S, et al.// Retina. - 2011. - 31(1). - С.26-30.https://doi.org/10.1097/IAE.0b013e3181de5609
Toalster N. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration/ Russell M, Ng P// Retina. - 2013. - 33(7). - С.1351-1358.https://doi.org/10.1097/IAE.0b013e3182831265
Hassan TS. Patient perceptions of the treatment regimen and expected outcomes of intravitreal anti-VEGF injections for wet age-related macular degeneration/ Luo CK, Willimas GA. Paper presented at: American Society of Retina Specialists Annual Meeting// August 25-29. - 2012. - Las Vegas, NV.
Egh?j MS. Tachyphylaxis during treatment of exudative age-related macular degeneration with Ranibizumab/ S?rensen TL// Br J Ophthalmol. - 2012. - 96(1). - С.21-23.https://doi.org/10.1136/bjo.2011.203893
Gasperini JL. Bevacizumab and Ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation/ Fawzi AA, Khondkaryan A, et al.// Br J Ophthalmol. - 2012. - 96(1). - С.14-20.https://doi.org/10.1136/bjo.2011.204685
Cho H. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab/ Shah CP, Weber M, Heier JS// Br J Ophthalmol. - 2013. - 97(8). - С.1032-1035.https://doi.org/10.1136/bjophthalmol-2013-303344
Lyall DA. Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes/ Tey A, Foot B, et al. // Eye (Lond). - 2012. - 26(12). - С.1517-1526.https://doi.org/10.1038/eye.2012.199
McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies/Retina. - 2011. - 31(4). - С.654-661.https://doi.org/10.1097/IAE.0b013e31820a67e4
Doshi RR. Reducing oral flora contamination of Intravitreal injections with face mask or silence/ Leng T, Fung AE// Retina. - 2012. - 32(3). - С.473-476.https://doi.org/10.1097/IAE.0b013e31822c2958
Wen JC. Bacterial dispersal associated with speech in the setting of intravitreous injections/ McCannel CA, Mochon AB, Garner OB// Arch Ophthalmol. - 2011. - 129(12). - С.1551-1554.https://doi.org/10.1001/archophthalmol.2011.227
Lavole D. Victims in meningitis outbreak hope for criminal charges against compounding pharmacy/ NBC News Digital// November 25, 2013.http://www.nbcnews.com/health/victims-meningitis-outbreak-hope-criminal-. - Accessed December 2, 2013.
Король А. Р. Сравнительный анализ эффективности лечения пациентов с экссудативной формой возрастной дегенерации макулы ингибиторами ангиогенеза в зависимости от степени тяжести / А. Р. Король // Офтальмол. журн. - 2013 - № 1. - С. 30-37.
Король А. Р. Гемодинамика в сосудистой оболочки у пациентов с экссудативной формой ВДМ в ходе лечения ингибиторами ангиогенеза и значение медикаментозной коррекции / А. Р. Король, Н. И. Храменко, О. С. Задорожный и др. // Офтальмол. журн. - 2013 - № 2. - С. 51-55.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 С. В. Шамбра, С. А. Федченко, О. В. Рябчун, О. Н. Блавацкая, А. Р. Король
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
